10-Q: LifeMD Extends Lease, Reports Strong Revenue Growth in Q3 2024

LifeMD, Inc. has extended its office lease and reported a 38% increase in revenue for the third quarter of 2024, driven by telehealth services.

Summary

• LifeMD, Inc. has extended its lease at 236 Fifth Avenue, New York, through May 31, 2028, with a rent abatement period until May 31, 2025.
• The company reported a 38% increase in total revenue for the three months ended September 30, 2024, reaching $53.4 million, compared to $38.6 million in the same period of 2023.
• Telehealth revenue saw a significant increase of 65%, while WorkSimpli revenue decreased by 8% during the same period.
• The company's gross profit increased by 43% to $48.4 million for the quarter, compared to $33.8 million in the same period of 2023.
• Operating expenses increased by 38% to $53.1 million, primarily due to higher selling and marketing costs.
• LifeMD reported a net loss attributable to common stockholders of $5.9 million for the quarter, compared to a net loss of $6.9 million in the same period of 2023.
• For the nine months ended September 30, 2024, total revenue was $148.2 million, a 38% increase compared to $107.7 million for the same period in 2023.
• Telehealth revenue increased by 62% for the nine months ended September 30, 2024, while WorkSimpli revenue decreased by 3% during the same period.
• The company's gross profit for the nine months ended September 30, 2024, was $133.6 million, a 42% increase compared to $94.1 million for the same period in 2023.
• Operating expenses for the nine months ended September 30, 2024, increased by 42% to $150.7 million.
• The net loss attributable to common stockholders for the nine months ended September 30, 2024, was $21.1 million, compared to a net loss of $19.2 million for the same period in 2023.

Sentiment

Score: 6

Explanation: The document shows strong revenue growth and strategic moves into new markets, but the continued net losses and identified material weaknesses in internal controls temper the overall positive outlook. The company's reliance on future capital raises also adds a layer of risk.

Positives

• The lease extension provides stability for the company's operations.
• The significant increase in telehealth revenue indicates strong growth in the company's core business.
• The increase in gross profit demonstrates improved profitability.
• The company has a strong cash position of $37.6 million as of September 30, 2024.
• The company has $53.3 million available under the ATM Sales Agreement, which is part of the $150.0 million available under the 2024 Shelf.

Negatives

• Operating expenses increased significantly, offsetting some of the revenue gains.
• The company continues to experience net losses, although the loss attributable to common stockholders decreased slightly for the quarter.
• WorkSimpli revenue decreased by 8% for the three months ended September 30, 2024.
• WorkSimpli revenue decreased by 3% for the nine months ended September 30, 2024.
• The company has an accumulated deficit of approximately $235 million.

Risks

• The company's continued operations are dependent on increasing sales volumes or issuing additional shares of common stock.
• There is no assurance that the company will be successful in increasing revenues and improving operational efficiencies.
• The company is subject to certain affirmative and negative covenants under the Avenue Facility, including maintaining a minimum cash balance and a trailing six-month cash flow.
• The company is dependent on third-party manufacturers and pharmacies.
• FDA potential restrictions on compounding of GLP-1s could disrupt patient treatment continuity and adversely impact financial results.
• The company has identified material weaknesses in its internal control over financial reporting.

Future Outlook

The company expects its burn rate of cash to continue to improve and to maintain positive operating cash flows for the next 12 months following the date of this report. The company plans to continue to introduce new telehealth product and service offerings that complement its already expansive treatment areas.

Management Comments

• The Company believes that its success has been, and will continue to be, attributable to an amazing patient experience, made possible by attracting and retaining the highest-quality providers in the country, and our proprietary end-to-end technology platform.
• The Company believes that its seamless approach significantly reduces the complication, cost and time burden of healthcare, incentivizing consumers to stick with our brands.

Industry Context

The telehealth market is experiencing rapid growth, and LifeMD is positioning itself to capitalize on this trend with its virtual primary care and specialized telehealth brands. The company's expansion into the GLP-1 weight management market aligns with the growing demand for medically supported weight loss solutions.

Comparison to Industry Standards

• LifeMD's 65% increase in telehealth revenue for the quarter is a strong indicator of growth compared to industry averages, though specific benchmarks vary widely.
• The company's gross profit margin of 90% for the quarter is competitive within the telehealth sector, but it is important to compare this to companies with similar business models.
• The company's operating expenses are high, which is common for growth-stage companies in the telehealth industry, but it is important to monitor these expenses relative to revenue growth.
• Companies like Teladoc Health and Amwell are major players in the telehealth space, and LifeMD's growth and financial performance should be compared to these industry leaders.
• The company's expansion into the GLP-1 weight management market is a strategic move, as this market is projected to grow significantly, but it is important to compare LifeMD's performance to other companies in this space, such as Ro and Hims & Hers.

Legal Proceedings

• On August 23, 2023, a purported putative class action complaint was filed against the company's RexMD brand.
• On September 5, 2023, the Internal Revenue Service issued a notice of deficiency to the Company in which the IRS asserted an income tax deficiency of approximately $ 1.9 million for the Companys tax year ending December 31, 2019.

Related Party Transactions

• The company utilized CloudBoson Technologies Pvt. Ltd., a company owned by WorkSimplis Chief Software Engineer, for software development services.
• The company utilized King & Spalding LLP, for which one of the company's Board of Directors immediate family members is the company's relationship partner, to provide legal services.
• Will Febbo, Robert Jindal, and Naveen Bhatia, members of the Board of the Company, entered into consulting services agreements with the Company.
• Brian Schreiber, Logistics & Fulfillment Advisor, and a relative of the Company's Chief Executive Officer, entered into an amended employment agreement.

Stakeholder Impact

• Shareholders may be concerned about the continued net losses and the need for potential capital raises.
• Employees may be affected by the company's efforts to improve operational efficiencies and address internal control weaknesses.
• Customers may benefit from the company's expansion into new telehealth services and its focus on improving the patient experience.
• Suppliers and creditors may be impacted by the company's financial performance and its ability to meet its obligations.

Next Steps

• The company plans to continue to introduce new telehealth product and service offerings.
• The company will continue to implement measures designed to ensure that control deficiencies contributing to the material weaknesses are remediated.

Key Dates

Keywords

telehealth, revenue, lease, LifeMD, WorkSimpli, financial results, operating expenses, gross profit, net loss, GLP-1, pharmacy, healthcare, subscription, weight management